News
MyChesCo on MSN2mon
Savara Inc. Publishes Promising Long-Term Outcomes for aPAP TreatmentThe retrospective case series evaluated the outcomes of five aPAP patients treated with molgramostim through European ...
Hosted on MSN18d
Savara Completes BLA Submission for MOLBREEVI to Treat aPAP“Submission of the BLA marks an important milestone for the Company and the aPAP community,” said Matt Pauls, Chair and Chief Executive Officer of Savara. “We believe this unprecedented body ...
As of December 31, 2024, the company had cash, cash equivalents and short-term investments of $196.3M. “Completing submission of the BLA is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback